메뉴 건너뛰기




Volumn 7, Issue 6, 2011, Pages 765-774

Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia

Author keywords

antisense oligonucleotide; antisense oligonucleotide therapy; Bcl 2; chronic lymphocytic leukemia; oblimersen sodium; phosphorothioate oligonucleotide

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; OBLIMERSEN; PROTEIN BCL 2; RITUXIMAB;

EID: 79956072494     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.579105     Document Type: Article
Times cited : (27)

References (50)
  • 3
    • 0037408455 scopus 로고    scopus 로고
    • Determining the clinical course and outcome in chronic lymphocytic leukemia
    • DOI 10.1056/NEJMe030032
    • Rai KR, Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 2003;7:1797-9 (Pubitemid 36514711)
    • (2003) New England Journal of Medicine , vol.348 , Issue.18 , pp. 1797-1799
    • Rai, K.R.1    Chiorazzi, N.2
  • 4
    • 36448982918 scopus 로고    scopus 로고
    • Oblimersen for the treatment of patients with chronic lymphocytic leukemia
    • Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007;3:855-70 (Pubitemid 350162084)
    • (2007) Therapeutics and Clinical Risk Management , vol.3 , Issue.5 , pp. 855-870
    • Cheson, B.D.1
  • 5
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 9
    • 0037220152 scopus 로고    scopus 로고
    • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712)
    • DOI 10.1182/blood-2002-04-1258
    • Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14 (Pubitemid 36025880)
    • (2003) Blood , vol.101 , Issue.1 , pp. 6-14
    • Byrd, J.C.1    Peterson, B.L.2    Morrison, V.A.3    Park, K.4    Jacobson, R.5    Hoke, E.6    Vardiman, J.W.7    Rai, K.8    Schiffer, C.A.9    Larson, R.A.10
  • 11
    • 70449723145 scopus 로고    scopus 로고
    • 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
    • O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27:5208-12
    • (2009) J Clin Oncol , vol.27 , pp. 5208-5212
    • O'Brien, S.1    Moore, J.O.2    Boyd, T.E.3
  • 12
    • 77950524161 scopus 로고    scopus 로고
    • Improving FCR immunochemotherapy in CLL
    • Robak T. Improving FCR immunochemotherapy in CLL. Blood 2010;115:437-8
    • (2010) Blood , vol.115 , pp. 437-438
    • Robak, T.1
  • 13
    • 34548490096 scopus 로고    scopus 로고
    • New treatments for chronic lymphocytic leukemia
    • DOI 10.1007/s11912-007-0047-7
    • Chanan-Khan AA. New treatments for chronic lymphocytic leukemia. Curr Oncol Rep 2007;9:353-60 (Pubitemid 47377066)
    • (2007) Current Oncology Reports , vol.9 , Issue.5 , pp. 353-360
    • Chanan-Khan, A.A.1
  • 14
    • 0026696155 scopus 로고
    • Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
    • Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-9
    • (1992) Blood , vol.79 , pp. 2981-9
    • Schena, M.1    Larsson, L.G.2    Gottardi, D.3
  • 15
    • 0027239823 scopus 로고
    • Bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
    • Hanada M, Delia D, Aiello A, et al. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-8 (Pubitemid 23278773)
    • (1993) Blood , vol.82 , Issue.6 , pp. 1820-1828
    • Hanada, M.1    Delia, D.2    Aiello, A.3    Stadtmauer, E.4    Reed, J.C.5
  • 17
    • 0029871942 scopus 로고    scopus 로고
    • Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome
    • Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-9 (Pubitemid 26128784)
    • (1996) Leukemia , vol.10 , Issue.3 , pp. 456-459
    • Robertson, L.E.1    Plunkett, W.2    McConnell, K.3    Keating, M.J.4    McDonnell, T.J.5
  • 18
    • 0036971988 scopus 로고    scopus 로고
    • Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients
    • Klobusicka M, Kusenda J, Babusikova O. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma 2002;49:387-93 (Pubitemid 36139239)
    • (2002) Neoplasma , vol.49 , Issue.6 , pp. 387-393
    • Klobusicka, M.1    Kusenda, J.2    Babusikova, O.3
  • 22
    • 0031981143 scopus 로고    scopus 로고
    • Mechanisms of Bcl-2 protein function
    • Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998;13:521-30
    • (1998) Histol Histopathol , vol.13 , pp. 521-530
    • Wang, H.G.1    Reed, J.C.2
  • 23
    • 0031464448 scopus 로고    scopus 로고
    • Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
    • Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997;34:9-19 (Pubitemid 28032415)
    • (1997) Seminars in Hematology , vol.34 , Issue.SUPPL. 5 , pp. 9-19
    • Reed, J.C.1
  • 24
    • 0029897734 scopus 로고    scopus 로고
    • Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX
    • McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996;156:2624-30 (Pubitemid 26091593)
    • (1996) Journal of Immunology , vol.156 , Issue.7 , pp. 2624-2630
    • McConkey, D.J.1    Chandra, J.2    Wright, S.3    Plunkett, W.4    McDonnell, T.J.5    Reed, J.C.6    Keating, M.7
  • 25
    • 0029978058 scopus 로고    scopus 로고
    • Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance
    • Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-62 (Pubitemid 26104447)
    • (1996) Oncogene , vol.12 , Issue.5 , pp. 1055-1062
    • Thomas, A.1    El Rouby, S.2    Reed, J.C.3    Krajewski, S.4    Silber, R.5    Potmesil, M.6    Newcomb, E.W.7
  • 30
    • 0034667624 scopus 로고    scopus 로고
    • Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
    • Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63
    • (2000) Blood , vol.96 , pp. 2655-2663
    • Burger, J.A.1    Tsukada, N.2    Burger, M.3
  • 31
    • 23944488816 scopus 로고    scopus 로고
    • Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
    • DOI 10.1182/blood-2004-12-4918
    • Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30 (Pubitemid 41208600)
    • (2005) Blood , vol.106 , Issue.5 , pp. 1824-1830
    • Burger, M.1    Hartmann, T.2    Krome, M.3    Rawluk, J.4    Tamamura, H.5    Fujii, N.6    Kipps, T.J.7    Burger, J.A.8
  • 32
    • 23044514711 scopus 로고    scopus 로고
    • Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
    • DOI 10.1182/blood-2004-03-0889
    • Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-20 (Pubitemid 41076448)
    • (2005) Blood , vol.106 , Issue.3 , pp. 1012-1020
    • Nishio, M.1    Endo, T.2    Tsukada, N.3    Ohata, J.4    Kitada, S.5    Reed, J.C.6    Zvaifler, N.J.7    Kipps, T.J.8
  • 34
    • 15244355253 scopus 로고    scopus 로고
    • Bcl-2 antisense therapy in B-cell malignancies
    • DOI 10.1016/j.blre.2004.11.002
    • Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005;19:213-21 (Pubitemid 40387412)
    • (2005) Blood Reviews , vol.19 , Issue.4 , pp. 213-221
    • Chanan-Khan, A.1
  • 35
    • 28844454167 scopus 로고    scopus 로고
    • Antisense strategies for oncogene inactivation
    • DOI 10.1053/j.seminoncol.2005.09.003, PII S0093775405003623, Gene Therapy of Cancer
    • Stein CA, Benimetskaya L, Mani S. Antisense strategies for oncogene inactivation. Semin Oncol 2005;32:563-72 (Pubitemid 41772684)
    • (2005) Seminars in Oncology , vol.32 , Issue.6 , pp. 563-572
    • Stein, C.A.1    Benimetskaya, L.2    Mani, S.3
  • 36
    • 0042398462 scopus 로고    scopus 로고
    • BCL-2 antisense therapy: In vitro, in vivo and human trial experiences in haematological malignancies
    • Cotter F. BCL-2 antisense therapy: in vitro, in vivo and human trial experiences in haematological malignancies. Naunyn-Schmiedebergs Arch Pharmacol 1998;358(Suppl 1):205
    • (1998) Naunyn-Schmiedebergs Arch Pharmacol , vol.358 , Issue.SUPPL. 1 , pp. 205
    • Cotter, F.1
  • 37
    • 34248157136 scopus 로고    scopus 로고
    • Phase I trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
    • DOI 10.1200/JCO.2006.09.5125
    • Rheingold SR, Hogarty MD, Blaney SM, et al. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007;25:1512-18 (Pubitemid 46733077)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1512-1518
    • Rheingold, S.R.1    Hogarty, M.D.2    Blaney, S.M.3    Zwiebel, J.A.4    Sauk-Schubert, C.5    Chandula, R.6    Krailo, M.D.7    Adamson, P.C.8
  • 39
    • 20644469046 scopus 로고    scopus 로고
    • Phase i study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
    • Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005;23:3404-11
    • (2005) J Clin Oncol , vol.23 , pp. 3404-3411
    • Marcucci, G.1    Stock, W.2    Dai, G.3
  • 40
    • 84871473548 scopus 로고    scopus 로고
    • A pharmacokinetic (PK) study of oblimersen sodium (G3139) + dacarbazine (DTIC) in patients with metastatic melanoma (MM)
    • American Society of Clinical Oncologists; 31 May - 3 Jun 2003; Chicago, Illinois, United States. J Clin Oncol
    • Demidov LV, Kharkevitch G, Itri LM, Frankel SR. A pharmacokinetic (PK) study of oblimersen sodium (G3139) + dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proceedings of the 39th Annual Meeting, American Society of Clinical Oncologists; 31 May - 3 Jun 2003; Chicago, Illinois, United States. J Clin Oncol 2003;22:156
    • (2003) Proceedings of the 39th Annual Meeting , vol.22 , pp. 156
    • Demidov, L.V.1    Kharkevitch, G.2    Itri, L.M.3    Frankel, S.R.4
  • 42
    • 32944475363 scopus 로고    scopus 로고
    • Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
    • DOI 10.1200/JCO.2005.02.4364
    • O'Brien SM, Cunningham CC, Golenkov AK, et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:7697-702 (Pubitemid 46291834)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.30 , pp. 7697-7702
    • O'Brien, S.M.1    Cunningham, C.C.2    Golenkov, A.K.3    Turkina, A.G.4    Novick, S.C.5    Rai, K.R.6
  • 45
    • 79960971061 scopus 로고    scopus 로고
    • Bcl-2 antisense (genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL Cells
    • Auer R, Corbo M, Fegan C. Bcl-2 antisense (Genasense ) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells [abstract 3358]. Proceedings of the 43rd Annual Meeting. Am Soc Hematol Blood 2001;98:808a (Pubitemid 33790617)
    • (2001) Blood , vol.98 , Issue.PART 1
    • Auer, R.L.1    Corbo, M.2    Fegan, C.D.3    Frankel, S.R.4    Cotter, F.E.5
  • 46
    • 0009794598 scopus 로고    scopus 로고
    • Manipulation of differentially expressed genes such as bcl-2 leads to increased killing of B chronic lymphocytic leukemia [abstract 3547]
    • Joshi S, Wang P, Dickinson J. Manipulation of differentially expressed genes such as bcl-2 leads to increased killing of B chronic lymphocytic leukemia [abstract 3547]. Proc Am Assoc Cancer Res 2001;42:659
    • (2001) Proc Am Assoc Cancer Res , vol.42 , pp. 659
    • Joshi, S.1    Wang, P.2    Dickinson, J.3
  • 47
    • 33745312907 scopus 로고    scopus 로고
    • Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia
    • Mavromatis B, Rai KR, Wallace PK, et al. Efficacy and Safety of the Combination of Genasense (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2005;106:2129
    • (2005) ASH Annual Meeting Abstracts , vol.106 , pp. 2129
    • Mavromatis, B.1    Rai, K.R.2    Wallace, P.K.3
  • 48
    • 79956084877 scopus 로고    scopus 로고
    • Impact of prognostic markers on outcomes in patients with advanced chronic lymphocytic leukemia treated with the regimen of fludarabine/ rituximab plus oblimersen (Bcl-2 Antisense) [abstract 6609]. 2006
    • Marvromatis B, Rai K, Wallace PK, et al. Impact of prognostic markers on outcomes in patients with advanced chronic lymphocytic leukemia treated with the regimen of fludarabine/ rituximab plus oblimersen (Bcl-2 Antisense) [abstract 6609]. 2006 ASCO Annual Meeting Proceedings; 2006. p. 24
    • (2006) ASCO Annual Meeting Proceedings , pp. 24
    • Marvromatis, B.1    Rai, K.2    Wallace, P.K.3
  • 49
    • 36448950375 scopus 로고    scopus 로고
    • Chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense ; G3139) in advanced chronic lymphocytic leukemia: Report of a large randomized study
    • Rai KR, Moore J, Boyd TE. Chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense ; G3139) in advanced chronic lymphocytic leukemia: report of a large randomized study. Leuk Lymphoma 2005;46(Suppl 1):S16
    • (2005) Leuk Lymphoma , vol.46 , Issue.SUPPL. 1
    • Rai, K.R.1    Moore, J.2    Boyd, T.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.